1. Pink Sheet
  2. >>R&D
  3. >>Clinical Trials

AI-Generated Plain Language Summaries Of Trial Results Can Save Time, But Need A Human Touch

 
• By Lauren Nardella

Staburo’s Kathi Künnemann examined the utility of artificial intelligence in developing plain language summaries for clinical trials results.

Artificial Intelligence Content Generator. A man uses a laptop to interact with AI assistant. AI offers functions like chatbot, generate images, write code, writer bot, translate and advertising. LLM.
AI in medical writing can be a significant time saving tool. (Shutterstock)
Key Takeaways
  • A case study by Staburo’s senior disclosure manager shows AI-generated plain language summaries of trial results, when reviewed by a medical writer, can match the quality of those created solely by a medical writer.
  • Using AI can significantly reduce the time required to create these summaries, aiding compliance with EU Clinical Trials Regulation, but AI outputs can be unreliable and require human correction.
  • Non-medical volunteers found both AI-assisted and human-only summaries to be of similar quality.

Plain language summaries of clinical trial results created with the help of the generative artificial intelligence tool, ChatGPT, and reviewed by a medical writer can achieve the same quality standards...

The findings highlight the potential benefits of using AI in clinical trial compliance processes but also emphasize the need for human supervision.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

Canada Cuts Red Tape With Single Ethics Review For Trials Clone

 
• By Neena Brizmohun

A new research ethics review system for multi-site clinical trials in Canada is expected to help improve study start-up times, avoid unnecessary duplication and boost the country’s competitiveness on a global stage.

US FDA’s Prasad: ‘We Will Always Embrace Surrogate Endpoints’

 
• By Sarah Karlin-Smith

The new CBER director, once best known in the pharma world for criticizing accelerated approval, committed to expediting cancer drugs with surrogate endpoints.

UK And US Regulators In Sync On RWD External Control Arms

 
• By Vibha Sharma

The UK regulator’s draft guideline on the use of external control arms based on real-world data reflects concepts similar to those outlined by the US Food and Drug Administration.

More from Geography

US FDA’s June Approval Forecast: Infection Prevention, Cancer And HAE

 
• By Bridget Silverman

Upcoming FDA user fee goal dates include novel products from a busy lung cancer pipeline, a single-dose passive immunization against RSV for infants, what could be the first oral HAE acute treatment, and a first-in-class HAE preventive antibody.

GLP-1 Pricing ‘Paradigm Shift’ Possible, But Would It Meet Trump’s MFN Goals?

 
• By Cathy Kelly

For the Trump Administration, the blockbuster GLP-1 drugs for obesity have become a poster child for the disparity between US and foreign prices.

Pink Sheet Podcast: US FDA’s Private Pharma CEO Tour, HHS Changes COVID-19 Vaccine Advice

 
• By Derrick Gingery, Sarah Karlin-Smith, Sue Sutter, and Nielsen Hobbs

Pink Sheet reporter and editors consider the issues that could emerge during upcoming private FDA forums with pharma CEOs, as well as the impact of the surprising move by HHS Secretary Robert F. Kennedy Jr. to limit the CDC recommendation for annual COVID-19 vaccine boosters.